Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

BACKGROUND: The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the sphingosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Camacho-Toledano, Celia, Machín-Díaz, Isabel, Calahorra, Leticia, Cabañas-Cotillas, María, Otaegui, David, Castillo-Triviño, Tamara, Villar, Luisa María, Costa-Frossard, Lucienne, Comabella, Manuel, Midaglia, Luciana, García-Domínguez, José Manuel, García-Arocha, Jennifer, Ortega, María Cristina, Clemente, Diego
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675277/
https://www.ncbi.nlm.nih.gov/pubmed/36403026
http://dx.doi.org/10.1186/s12974-022-02635-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675277/
https://www.ncbi.nlm.nih.gov/pubmed/36403026
http://dx.doi.org/10.1186/s12974-022-02635-3

Ejemplares similares